often practicing on Mrs. Andromahi Mavrogeni Papanicolaou. Following its introduction into clinical practice in the 1950s, the Pap smear has saved thousands of lives, further cementing the disease's novelty through cost-effective, non-invasive, reliable screening. Finally, from 1976-1984, the German virologist Harald zur Hausen (1936-) identified the etiologic role of human papillomavirus (HPV) subtypes 16 and 18 in the development of cervical cancer [7] , leading directly to high risk HPV DNA detection assays to augment cytologic screening through increased sensitivity. zur Hausen would ultimately receive the Nobel Prize in Physiology or Medicine in 2008 for this discovery. Not only has the identification of relevant viral DNA sequences allowed for the development of prophylactic HPV vaccination using virus-like particle technology incorporating a cDNA of the highly antigenic L1 HPV capsid protein, but the molecular cascade which governs virus-induced carcinogenesis has also been elucidated. Specifically, the HPV oncoproteins E6 and E7 degrade and inactivate the cellular tumor suppressor gene products, p53 and pRb, respectively, leading directly to dysregulation of the cell cycle [8] . Inflamed tumors develop through infection by high risk HPV subtypes and viral integration into host DNA which disrupts the viral regulatory E2 reading frame, resulting in loss of the negative feedback loop which otherwise prevents viral oncogene expression. With continued understanding of the immunologic tolerance taking place in the tumor microenvironment, we are finally in a position to consider therapeutic vaccination for this disease based on HPV oncogene expression. In a randomized, placebo-controlled phase 2 trial involving 129 women with CIN2-3 using the HPV 16 E6 and E7-based therapeutic vaccine, tipapkinogen sovacivec, complete resolution among vaccine-recipients with CIN3 was 21% (compared to 0% in the placebo arm) [9] .
In the September 2019 issue of the Journal of Gynecologic Oncology, Park and colleagues [10] have reported data from a phase 1/2a dose-escalation study of BLS-M07 to treat CIN3. The vaccine is novel and is orally administered five times each week (on weeks 1, 2, 4, and 8) at a dose of 1,000 mg. By embedding the HPV 16 E7 antigen on the surface of the Lactobacillus casei vaccine construct, the investigators were able to monitor disease regression using the Reid Colposcopic Index grading system and measure serum HPV 16 E7 antibody production. There were no grade 3 or 4 treatment-related adverse events or deaths observed among the 19 patients enrolled with CIN3. Importantly, not only did vaccination induce protective humoral immunity, but in phase 2a, six of eight subjects (75%) were cured at 16 weeks' follow-up [10]. This contrasts favorably with what is observed in clinical practice during which time regression rates of 25% may require up to 1 year or even longer.
The oral schedule, high efficacy, absence of notable side effects, and position during the preinvasive course of the disease represent clear advantages of this vaccine strategy. However, because the trial was not placebo-controlled and the investigators performing colposcopicdirected biopsies after vaccination may not have been blinded to the participation by the patients on the trial, the efficacy results will need further validation in a doublerandomized, placebo-controlled trial. In addition, in designing a confirmatory trial, a strong consideration for excisional biopsy (cold knife cervical conization or large loop excision of the transformation zone) should be made so as to pathologically confirm complete tumor regression induced by recipients of study vaccine. A revision of the administration schedule to fewer days and/or fewer weeks may have a positive impact on compliance in a real world setting, provided that efficacy is not compromised. Finally, applicability of this novel technology to patients with non-HPV 16 CIN3 along with analysis of viral DNA clearance through hybrid capture will also need to be addressed.
